home All News open_in_new Full Article

ACTG Presents Four Studies at CROI Describing Findings from SLIM LIVER

Presentations highlight relationship between semaglutide and blood markers of gene modification age predictors, gut bacteria, heart and metabolic effects, and fat in the liver LOS ANGELES, March 10, 2025 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced new findings from the SLIM LIVER study (also […]



ACTG presented four SLIM LIVER study findings at CROI 2025, demonstrating that semaglutide can improve or resolve MASLD in people living with HIV. One study suggests epigenetic biomarkers in blood may predict treatment response. Additional findings cover semaglutide's impact on gut bacteria, heart health, metabolism, and liver inflammation in this population.

today 3 d. ago attach_file Events

attach_file Society
attach_file Other
attach_file Politics
attach_file Culture
attach_file Society
attach_file Other
attach_file Events
attach_file Other
attach_file Other
attach_file Events
attach_file Other
attach_file Economics
attach_file Economics
attach_file Events
attach_file Events
attach_file Economics
attach_file Other
attach_file Politics
attach_file Events
attach_file Transport


ID: 3513342620
Add Watch Country

arrow_drop_down